A Phase Ib Study Of The Combination Of CD47 Blockade With SIRP-Alpha FC Fusion Proteins (TTI-622) And Daratumumab Hyaluronidase-fihj For Patients With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 05 Feb 2024
At a glance
- Drugs Daratumumab/hyaluronidase (Primary) ; Maplirpacept (Primary) ; Ontorpacept (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 26 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 17 May 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2025.
- 17 May 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2025.